Easton Pharmaceuticals Announces Projections of $15 Million in Revenue For 2012 From The Company’s First Territory Launch of VIORRA in Mexico

Posted by on Jul 22, 2011 in News | 0 comments

VIORRA is a Female Over-The-Counter Aid for Treatment to Restore and Improve Vaginal Moisture and Elasticity Plus Increase Sexual Desire

TORONTO, ONTARIO — (Marketwire) — 07/22/11 — Easton Pharmaceuticals (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products has been advised of by BMV Medica S.A. de C.V. (BMV), the company that was recently retained in Mexico to finalize regulatory approval and arrange distribution partnerships for the company’s first product launch in Mexico;

See full article from DailyFinance: http://srph.it/nOFl5m

— BMV Medica S.A. de C.V. (BMV) has advised that their initial market analysis and conversations with distribution partnerships for the company’s first product launch, VIORRA an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity, that also exhibits a very positive effect on women’s sexual desire and arousal FSAD (Female Sexual Arousal Disorder) could generate upwards of $15 million dollars in revenue within twelve months of product launch.

— Mexico represents an ideal first territory launch site for our VIORRA Female Sexual Dysfunction (FSAD) product, stated John Easton, CEO and Chairman of the board of Easton Pharmaceuticals, “As Male Sexual Dysfunction products have historically done very well in Mexico, and with a population of 120 million, the raw numbers of prospective female customers are very attractive to Easton Pharmaceuticals. The world market for these female conditions are estimated in excess of $2 billion.”

— BMV estimates the regulatory approval process will be completed in early 2012. In parallel with the regulatory filing, Easton Pharmaceuticals under the guidance of BMV has begun talks with several large distribution companies that are focused on sales and marketing in the women’s health market. Easton Pharmaceuticals” believes that with both the regulatory and commercial alliance initiatives running in parallel will enable a timely, successful launch of VIORRA and generate upwards of $15 million annual company revenue from Mexico beginning in 2012.

About Easton Pharmaceuticals

Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is estimated in excess of $10 billion. The company’s proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients (GRAS).

For More Information Visit www.eastonpharma.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “pleased,””plan,””confident that,””believe,””expect,””anticipate” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company’s financial reports and filings.

Copyright ©2011 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc.

Contacts:

Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291+1(416) 619-0291
Tel: +1(347) 284-0192+1(347) 284-0192
+1(888) 877-3723 (FAX)
Media relations: media@eastonpharma.com
Investor relations: ir@eastonpharma.com

Leave a Reply

Your email address will not be published. Required fields are marked *

* Copy This Password *

* Type Or Paste Password Here *